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Objective. Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a rare disease characterized by predominant upper lobe
pulmonary fibrosis of unknown etiology. However, the prognosis of IPPFE has not been discussed. We investigated the clinical
characteristics and prognostic factors of IPPFE and idiopathic pulmonary fibrosis (IPF). Methods. We performed a retro-
spective cohort study on 375 consecutive idiopathic interstitial pneumonia patients between April 2004 and December 2014.
Among them, we diagnosed IPPFE and IPF patients using high-resolution computed tomography radiological criteria. Results.
Twenty-nine IPPFE patients (9 males, 20 females) and 67 IPF patients (54 males, 13 females) were enrolled. IPPFE patients
were significantly more likely to be females and nonsmokers and had lower body mass index, lower values of predicted
percentage of forced vital capacity (%FVC), and a higher residual volume-to-total lung capacity ratio than IPF patients.
Survival analysis revealed that they had significantly poorer prognosis than IPF patients in GAP (gender, age, and physiology)
stages II + III. %FVC and GAP index independently predict mortality in patients with IPPFE. Conclusions. Patients with IPPFE
showed poorer prognosis in the advanced stage than patients with IPF. %FVC and GAP index are independent predictors of
survival in patients with IPPFE.
1. Introduction
Pleuroparenchymal fibroelastosis (PPFE) was initially de-
scribed as upper lobe pulmonary fibrosis of unknown eti-
ology by Amitani et al. [1]. In 2013, idiopathic PPFE (IPPFE)
was newly listed as a rare idiopathic interstitial pneumonia
(IIP) in the IIP classification [2]. ,e clinical characteristics
of IPPFE show a history of recurrent pneumothorax, re-
current infection, and weight loss [3]. High-resolution
computed tomography (HRCT) of IPPFE patients shows
upper lobe involvement with dense subpleural consolida-
tion, architectural distortion, and upper lobe volume loss [4].
However, the prognosis of IPPFE remains unclear. Oda et al.
[5] demonstrated that usual interstitial pneumonia (UIP)
with IPPFE is clinically different from UIP/idiopathic
pulmonary fibrosis (IPF) and that the former tended to have
a poor prognosis. Watanabe et al. [6] reported that IPPFE
patients show a rapid decrease in forced vital capacity (FVC).
From these reports, we speculated that IPPFE patients have
a poorer prognosis than IPF patients. IPPFE is generally
diagnosed via histological examination of the lung tissue.
However, surgical lung biopsy is a high-risk and invasive
diagnostic procedure for IIPs that can cause severe com-
plications. Because HRCT findings of IPPFE are distinctive
from those of the other IIPs [7–9], we consider HRCT to be
sufficient to diagnose IPPFE.
Here, we identified patients with IPPFE using HRCT
radiological criteria and compared the clinical profiles, blood
gas analysis, pulmonary function tests, and prognosis be-
tween IPPFE and IPF. We elucidated that the clinical
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features of IPPFE were different from those of IPF, and
IPPFE showed a poorer prognosis compared with IPF in
advanced stages.
2. Patients and Methods
2.1. Study Design. We performed a retrospective cohort
study of 375 consecutive IIPs patients at Sapporo Medical
University Hospital between April 2004 and December 2014.
,is study was approved by the Institutional Review Board
of Sapporo Medical University Hospital (#282–1052, ap-
proved on October 17, 2015), and the need for informed
consent from the patients was waived because of the ret-
rospective nature of the study. Of the 375 subjects, IPPFE
and IPF patients were selected and compared with regard to
their clinical parameters and survival. By reviewing their
radiological findings, laboratory data, clinical symptoms,
occupational history, living environment, and contact his-
tory to bird and other potential antigen, we excluded pa-
tients with cardiovascular, infectious, neoplastic, or allergic
diseases; those presenting with a lung disease due to ex-
posure to occupational dust, such as asbestosis; and those
presenting with tuberculosis, sarcoidosis, hypersensitivity
pneumonia, collagen vascular diseases, or a history of chest
operations.
2.2. IPPFE and IPF Diagnoses. Patients with pathologically
diagnosed IPPFE or radiologically diagnosed IPPFE were
selected and enrolled into this study. IPPFE patients were
diagnosed by four expert pulmonologists, without the
knowledge of the clinical information of the patients,
according to the HRCT radiological criteria for IPPFE di-
agnosis [10] as follows: definite IPPFE, pleural thickening
with associated subpleural fibrosis is upper lobe pre-
dominant with less marked or no involvement of the lower
lobes; consistent with IPPFE, pleural thickening with as-
sociated subpleural fibrosis is upper lobe dominant but the
distribution of these changes is not upper lobe dominant or
features of coexisting upper lobe pleural thickening are
present elsewhere but the distribution of all HRCT findings
is evidently upper lobe dominant; inconsistent with IPPFE,
lacking the requisite features described earlier. If there are
HRCT findings in the middle or lower lobe, these findings
are relatively limited compared to the PPFE lesion in the
upper lobe and discontinuous from the PPFE lesion. HRCT
findings were reviewed two or three times throughout the
clinical course. Patients were only included when they were
considered definite or consistent with IPPFE. In addition,
the histological criteria for PPFE [11] were applied to the
cases where the patients underwent surgical biopsy.
In addition, IPF patients were diagnosed according to
the 2011 American ,oracic Society (ATS)/European Re-
spiratory Society (ERS)/Japan Respiratory Society
(JRS)/Latin American ,oracic Association (ALAT) IPF
statement [12].
2.3. Clinical and Radiological Review. All subjects were
reviewed in terms of their clinical information, radiological
data, pulmonary function test (PFT) results, and laboratory
data from the medical records on the date of the first visit to
our hospital. We evaluated HRCT findings and the ratio of
the anteroposterior diameter of the thorax (APDT) to the
transthoracic diameter of the thorax (TDT) on the HRCT
using published criteria [12–14]. In the PFTs, we examined
the annual changes in the parameters, including FVC, total
lung capacity (TLC), residual volume (RV), and diffusing
capacity of the lung for carbon monoxide (DLco).
Survival analysis was performed from the date of the first
visit to our hospital. ,e overall survival of the IPPFE and
IPF groups was compared using the GAP (gender, age, and
physiology) index and staging system [15].
2.4. Statistical Analysis. All data were expressed as the
mean± standard deviation (SD) or 95% confidence interval.
Differences between the two groups were assessed using the
Mann–Whitney U test. A chi-square test or Fisher’s exact
test was used to compare categorical data. Survival analysis
was performed using the Kaplan–Meier method, and the log
rank test and the generalized Wilcoxon test were used to
compare the survival curves. ,e univariate Cox pro-
portional hazard model was used to examine the association
of the selected variables with survival. Variable selections in
multivariate analysis were performed with respect to age,
and variables with a p value less than 0.05 were analyzed by
the univariate analysis. Selected variables were age, sex,
clubbed finger, history of pneumothorax, GAP index, pre-
dicted percentage of forced vital capacity (%FVC), predicted
percentage of diffusion capacity (%DLco), alveolar-arterial
oxygen difference (A-aDO2), and Krebs von den Lungen
(KL-6). All tests were performed at a significance level of
p< 0.05, and statistical analyses were performed using IBM
SPSS Statistics (version 22; IBM Corp., NY, USA).
3. Results
3.1. IPPFE and IPF Patients. Among the 375 patients with
IIPs, we identified 29 IPPFE patients who met the radio-
logical criteria for IPPFE. Of these, radiological findings of 2
patients indicated definite IPPFE and those of 27 patients
were consistent with IPPFE. ,ree patients underwent
surgical lung biopsy and fulfilled the histological criteria for
PPFE. In contrast, we identified 67 IPF patients who met the
ATS/ERS/JRS/ALAT criteria [12]; of these, eight patients
underwent surgical lung biopsy and fulfilled the histological
criteria for IPF.
3.2. Demographic Features. ,e baseline features are sum-
marized in Table 1. In the IPPFE group, 9 were male and 20
were female (mean age± SD: 69± 7.3 years old). Patients
with IPPFE were significantly more likely to be female and
nonsmokers, have smoked for fewer pack-years, had a lower
body mass index, and had a lower APDT-to-TDT ratio than
IPF patients.,ree patients in the IPPFE group had a history
of pneumothorax. ,e symptoms in the IPPFE group were
cough (n � 13; 45%), dyspnea on exertion (n � 7; 24%),
clubbed finger (n � 6; 21%), and fine crackles (n � 25; 86%)
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at the first visit, as well as in the IPF group. A higher
percentage of the IPPFE group showed presenting symptom
(72% versus 48%) and a lower percentage of mass screening
(28% versus 52%) for the reasons of the first medical ex-
amination compared with the IPF group (p � 0.03).
3.3. PFT, BGA, Serum Biomarkers, and HRCT. ,e IPPFE
group showed significantly lower values of the predicted
percentage of FVC (%FVC) and higher values of forced
expiratory volume percent in one second (FEV1/FVC), RV-
to-TLC ratio (RV/TLC), and PaCO2 than the IPF group
(Table 2). ,e IPPFE group had significantly lower values of
surfactant protein (SP)-A and Krebs von den Lungen (KL)-
6, as well as a lower positive rate of serum KL-6 than the IPF
group. Two patients (anti-CCP antibody and anti-dsDNA
antibody) in the IPPFE group and four patients (anti-SS-A
antibody, anti-Scl-70 antibody, and anti-CCP antibody) in
the IPF group showed positivity of specific autoantibodies.
,e HRCT findings of IPPFE patients are summarized in
Table 3. Totally, all 29 patients with IPPFE demonstrated
marked subpleural consolidation in the bilateral upper lobes.
Nine patients (31%) had accompanying honeycombing and
27 (93%) had traction bronchiectasis in the upper lobes.
Moreover, 10 patients (34%) demonstrated a definite UIP
pattern, seven (24%) a possible UIP pattern, and 10 (35%)
a nonspecific interstitial pneumonia (NSIP) pattern in the
middle or lower lobes.
3.4. Outcome, Events, and Survival. Eleven patients (38%) in
the IPPFE group and 29 (43%) in the IPF group died during
the observation period. In the IPPFE group, four patients
died of chronic respiratory failure, four of acute exacerba-
tion, and three of other causes, namely, pneumonia, pul-
monary embolism, and suicide (Table 4). Nineteen patients
in the IPPFE group and four in the IPF group had pneu-
mothorax or pneumomediastinum. Eight (73%) of IPPFE
patients who died had a history of pneumothorax or
pneumomediastinum. Moreover, we had one patient with
prolonged pneumothorax after surgical lung biopsy and one
patient with prolonged pneumothorax leading to acute
exacerbation. Two of the nine IPPFE patients treated with
oral corticosteroids showed improvements on HRCT.,ose
who showed restrictive ventilatory defects did not show
improvements in the PFT results. One of the 10 IPPFE
patients treated with pirfenidone maintained their %FVC
values for over a year whereas the others did not during the
observation period.
Seventeen patients in the IPPFE group and 57 patients in
the IPF group underwent PFT twice a year (mean interval,
1.03± 0.22 years; Table 5). ,e IPPFE group showed sig-
nificantly lower values of annual changes in FVC and TLC
than the IPF group.
,emean lengths of observation period in the IPPFE and
IPF groups were 64± 10 and 74± 5.3 months, respectively.
,e survival analysis showed that the IPPFE group had
significantly worse survival than the IPF group (log rank
p � 0.177, the generalized Wilcoxon p � 0.009; Figure 1(a)).
,ereafter, based on the GAP index and staging system,
IPPFE and IPF patients were classified into two stages: GAP
stage I and GAP stages II + III. In the GAP stage I, there was
no significant difference in survival between the IPPFE and
IPF groups (Figure 1(b)). In contrast, the IPPFE group
showed significantly worse survival than the IPF group in the
GAP stages II + III (log rank p � 0.001, the generalized
Wilcoxon p � 0.001; Figure 1(c)).
3.5. Evaluation of the Prognostic Factors in IPPFE Patients.
,e univariate Cox proportional hazard model demon-
strated that the following variables had statistically signifi-
cant effects on survival: female, clubbed finger, pack-years of
smoking, history of pneumothorax, GAP index, GAP stage,
%FVC, predicted percentage of TLC (%TLC), %DLco,
predicted percentage of diffusing capacity divided by the
alveolar volume (%DLco/VA), A-aDO2, KL-6, ΔFVC, and
ΔTLC (Table 6). In addition, the frequency of lower lobe
involvement in IPPFE patients showed no significant effect
on survival (Table 6).
,e multivariate Cox proportional hazard model dem-
onstrated that GAP index (HR: 2.510, p � 0.010) and %FVC
(HR: 0.903, p � 0.017) independently predict mortality in
patients with IPPFE.
4. Discussion
,e prognosis of IPPFE has not been fully investigated. In
the present study, we elucidated the differences between
IPPFE and IPF with respect to the clinical characteristics,
laboratory results, annual changes of pulmonary functions,
and survival. ,e prognosis of patients with IPPFE was
significantly poorer than that of patients with IPF, and %
FVC and GAP index were significantly associated with
poorer prognosis of IPPFE. As per our knowledge, there was
Table 1: ,e baseline characteristics of IPPFE and IPF patients.
IPPFE IPF
p value(n � 29) (n � 67)
Sex M/F 9/20 54/13 <0.01
Age (years) 69± 7.3 69± 7.8 0.81
Smoker/nonsmoker 11/18 56/11 <0.01
Number of pack-years 10.2± 20.0 34.7± 27.0 <0.01
History of pneumothorax 3 (10%) 1 (1.4%) 0.08
Family history of IPs 3 (10%) 10 (14.9%) 0.40
BMI (kg/m2) 20.1± 3.25 24.1± 2.97 <0.01
,oracic dimensions
APDT/TDT (%) 59.9± 6.0 65.4± 5.2 <0.01
Symptoms
Cough 13 (45%) 20 (30%) 0.16
Dyspnea on exertion 7 (24%) 13 (19%) 0.60
Clubbed finger 6 (21%) 16 (24%) 0.73
Fine crackles 25 (86%) 65 (97%) 0.07
First medical examination
Symptomatic 21 (72%) 32 (48%) 0.03
Mass screening 8 (28%) 35 (52%)
Data presented as the mean± SD or numbers. IP� interstitial pneumonia;
BMI� body mass index; APDT�anteroposterior diameter of the thorax;
TDT� transverse diameter of the thorax.
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only one prognostic article, which stated that the survival
time of patients with PPFE with UIP pattern tended to be
shorter than that of patients with IPF/UIP [5]. In our study,
there were differences in PFT at the time of diagnosis, with
significantly lower %FVC and higher RV/TLC in the IPPFE
group than in the IPF group; therefore, we compared the
prognosis between the two groups using the GAP index and
staging system. ,e GAP index and staging system is
a validated risk prediction model for mortality among pa-
tients with IPF [15]. We demonstrated that IPPFE patients
had significantly poorer prognosis than all IPF and those at
the GAP stage II + III. ,ese results may indicate that IPPFE
is more deteriorative than IPF in the advanced stage. Fur-
thermore, GAP index was a significant prognostic factor for
patients with IPPFE. ,ese results suggest that GAP index
may also predict mortality in patients with IPPFE.
Approximately 60% of patients with IPPFE with
a coexisting UIP pattern in the lower lobes were observed in
the present study. Despite IPPFE involving UIP lesions in
the lower lobe, the clinical features and prognosis of IPPFE
and IPF were completely different. ,ree previous studies
Table 2: ,e baseline physiological characteristics and laboratory results of IPPFE and IPF patients.
IPPFE IPF
p value(n � 29) (n � 67)
FVC %pred (%) 71.8± 19.4 88.2± 18.5 <0.01
FEV1/FVC (%) 86.0± 13.2 82.8± 7.29 <0.01
TLC %pred (%) 74.3± 14.2 78.3± 16.3 0.21
RV %pred (%) 76.9± 18.5 68.1± 19.3 0.10
RV/TLC (%) 40.2± 9.15 29.6± 6.90 <0.01
DLco %pred (%) 52.4± 12.9 (n � 24) 51.7± 14.8 (n � 61) 0.55
SpO2 (%) 96.6± 1.50 96.3± 1.58 0.42
A-aDO2 (Torr) 12.2± 11.1 (n � 27) 13.0± 7.45 (n � 62) 0.57
PaCO2 (Torr) 43.4± 3.57 (n � 27) 40.8± 3.40 (n � 62) <0.01
ANA (<320/≥320) 24/5 61/6 0.30
SP-A (ng/ml) 61.2± 22.3 84.2± 45.1 <0.01
SP-A (<43.8/≥43.8 ng/ml) 6/23 7/60 0.15
SP-D (ng/ml) 308± 204 258± 154 0.40
SP-D (<110/≥110 ng/ml) 4/25 9/58 0.60
KL-6 (U/ml) 894± 565 1225± 701 <0.01
KL-6 (<500/≥500U/ml) 8/21 5/62 0.01
GAP index 3.9± 1.8 3.6± 1.4 0.43
Data presented as the mean± SD or numbers. FVC� forced vital capacity; FEV1� forced expiratory volume in 1 s; TLC� total lung capacity; RV� residual
volume; DLco� diffusing capacity of the lung for carbon monoxide; SpO2 � arterial oxygen saturation measured by pulse oximetry; A-aDO2 � alveolar-
arterial oxygen difference; ANA� antinuclear antibody; KL-6�Krebs von den Lungen-6; SP� surfactant protein; GAP� (gender (G), age (A), and two lung
physiology variables (P) (FVC and DLco)).
Table 3: Radiological findings in IPPFE patients.
HRCT findings Number





Middle or lower lobe involvement 27
Definite UIP pattern 10
Possible UIP pattern 7
NSIP pattern 10
HRCT� high-resolution computed tomography; UIP� usual interstitial
pneumonia; NSIP� nonspecific interstitial pneumonia.
Table 4: Outcomes and events during the follow-up period.
IPPFE IPF





Chronic respiratory failure 4 11
Acute exacerbation 4 12




pneumomediastinum 19 4 <0.01
Recurrent infection 2 3 NS
Treatment NS
Oral corticosteroids 9 17
Immunosuppressant drugs 2 13
Pirfenidone 10 31
Home oxygen therapy 6 26




(n � 57) p value
Observation period (years) 1.01± 0.19 1.03± 0.24 0.59
ΔFVC (L) –0.28± 0.27 –0.11± 0.26 0.02
ΔTLC (L) –0.32± 0.26 –0.06± 0.39 0.01
ΔRV (L) –0.04± 0.18 –0.07± 0.56 0.83
ΔDLco (ml/min/mmHg) –0.70± 1.95 –0.45± 1.60 0.87
Data presented as the mean± SD. Changes in the pulmonary function
parameters as assessed at the 1-year follow-up appointment. FVC� forced
vital capacity; TLC� total lung capacity; RV� residual volume;
DLco� diffusing capacity of the lung for carbon monoxide.
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Figure 1: Kaplan–Meier survival curves. (a) Overall, the IPPFE group had significantly worse survival than the IPF group (log rank
p � 0.177, generalizedWilcoxon p � 0.009). (b) In the GAP stage I, there was no significant difference between the IPPFE and IPF groups in
terms of survival. (c) In the GAP stages II + III, the IPPFE group had significantly worse survival than the IPF group (log rank p � 0.001, the
generalized Wilcoxon p � 0.001).
Table 6: Prognostic factors for the overall survival of IPPFE patients during the follow-up period.
Parameter HR (95% CI) p value
Univariate Cox proportional hazards model
Age 0.967 (0.887–1.053) 0.436
Sex (F/M) 4.866 (1.422–16.650) 0.012
Clubbed finger (p/n) 4.032 (1.098–14.801) 0.036
Fine crackles (p/n) 1.609 (0.338–7.658) 0.550
APDT/TDT (%) 0.983 (0.892–1.084) 0.737
BMI 0.990 (0.813–1.206) 0.921
Smoking history (y/n) 3.014 (0.876–10.374) 0.080
Pack-years 1.024 (1.004–1.045) 0.020
History of pneumothorax 7.829 (1.256–48.45) 0.027
GAP index 1.675 (1.153–2.435) 0.007
GAP stages (II + III/I) 10.841 (2.258–52.048) 0.003
SpO2 (%) 1.141 (0.708–1.838) 0.588
FVC %pred (%) 0.946 (0.909–0.984) 0.006
FEV1/FVC (%) 0.998 (0.954–1.043) 0.912
TLC %pred (%) 0.883 (0.824–0.953) 0.001
RV %pred (%) 0.992 (0.961–1.025) 0.642
RV/TLC %pred (%) 1.001 (0.984–1.018) 0.903
DLco %pred (%) 0.866 (0.799–0.939) <0.001
DLco/VA %pred (%) 0.895 (0.831–0.964) 0.003
PaCO2 (Torr) 1.086 (0.909–1.298) 0.361
A-aDO2 (Torr) 1.090 (1.018–1.167) 0.013
ANA (40≥/40<) 1.144 (0.334–3.923) 0.831
SP-A (ng/ml) 1.006 (0.983–1.031) 0.604
SP-D (ng/ml) 1.001 (0.998–1.004) 0.601
KL-6 (U/ml) 1.001 (1.000–1.002) 0.027
ΔFVC (L) 0.016 (0.001–0.433) 0.014
ΔTLC (L) 0.001 (0.000–0.113) 0.005
ΔRV (L) 0.018 (0.000–1.811) 0.088
ΔRV/TLC (%) 1.018 (0.838–1.236) 0.857
ΔDLco (ml/min/mmHg) 0.021 (0.000–50180) 0.607
Lower lobe involvement (definite UIP and possible UIP/NSIP) 2.199 (0.626–7.730) 0.219
Multivariate Cox proportional hazards model
GAP index 2.510 (1.245–5.059) 0.010
FVC %pred (%) 0.903 (0.830–0.982) 0.017
APDT�anteroposterior diameter of the thorax; TDT� transverse diameter of the thorax; BMI� body mass index; GAP� (gender (G), age (A), and two lung
physiology variables (P) (FVC and DLco)); SpO2 � arterial oxygen saturation measured by pulse oximetry; FVC� forced vital capacity; FEV1� forced
expiratory volume in 1 s; TLC� total lung capacity; RV� residual volume; DLco� diffusing capacity of the lung for carbon monoxide; A-aDO2 � alveolar-
arterial oxygen difference; ANA� antinuclear antibody; SP� surfactant protein; KL-6�Krebs von den Lungen-6.
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reported rates of the presence of a coexisting UIP pattern to
be 54% [7], 43% [10], and 75% [16]. ,us, a coexisting UIP
pattern in the lower lobes may be characteristic in IPPFE
patients. In contrast, the cause of death in IPPFE patients
included acute exacerbations, which are also found in IPF.
As IPPFE progresses, not only chronic respiratory failure but
also acute exacerbations may be involved [17]. We speculate
that UIP lesions in the lower lobes are possibly the origin of
these acute exacerbations.
Although we diagnosed IPPFE using the radiological
criteria, the clinical features of patients with IPPFE diagnosed
using radiological criteria were thought to be consistent with
the characteristics of pathologically diagnosed patients with
PPFE previously reported [6, 11, 16–19]. IPPFE diagnosis is
generally made via histological examination of the lung tissue.
However, surgical lung biopsy is a high-risk and invasive
diagnostic procedure for IIPs that can cause severe compli-
cations. Postoperative pneumothorax is a frequent compli-
cation in the surgical lung biopsy of patients with PPFE [10].
Most patients with IPPFE in this study were unable to un-
dergo surgical lung biopsy because of the advanced stage
during diagnosis. Camus et al. [7] proposed that surgical lung
biopsy is unnecessary for cases that clinically and radiolog-
ically meet IPPFE characteristics. Because the radiological
characteristics of PPFE are very distinctive compared with
those of other ILDs, the possibility of radiological diagnosis
using HRCT has been proposed [7–9]. We think that the
radiological criteria reported by Reddy et al. [10] are ap-
propriate for the clinical diagnosis of IPPFE.
Eighteen of the 29 (62.1%) patients were treated with
corticosteroids or pirfenidone after diagnosis. Corticoste-
roids were often used to treat patients in this study with
acute or subacute progressive diseases. ,ese patients
showed improvements on HRCT but not in the PFT results.
Only one of the nine (11%) patients treated with pirfenidone
was able to maintain their %FVC for over a year. ,ese
treatments were not previously considered as effective for
IPPFE patients who reportedly have similar characteristics
[17]. However, pirfenidone was effective for treating IPPFE
combined with UIP in the lower lobes [20]. Pirfenidone may
be an effective drug for IPPFE patients with a UIP lesion
because it reduces the progression of fibrotic changes.
Further research is warranted to examine the efficacy of
pirfenidone in IPPFE patients.
Here, patients with IPPFE showed significantly lower
serum SP-A and KL-6 levels than patients with IPF.
According to two previous reports on the same nine IPPFE
cases [18, 21], the serum SP-D level was higher than the
normal value in all cases; conversely, the KL-6 level in-
creased in only three cases. It is still unclear why the serum
SP-D level is highly elevated, whereas the KL-6 level is
normal or slightly higher than the normal range in most
IPPFE patients. Sato et al. [21] reported that their immu-
nohistochemical analysis for SP-D demonstrated that the
hyperplastic epithelial cells in the upper lobes were more
strongly stained than those in the lower lobes, although they
found that KL-6 was homogeneously stained in the lung
tissues of both the upper and lower lobes. ,ese differences
may contribute to serum biomarker elevations in IPPFE.
Our study had several limitations. First, this was a ret-
rospective cohort study conducted at only a single institute.
Second, we did not perform pathological assessments;
however, we carefully considered other etiologies of upper
lobe fibrosis, such as occupational dust exposure, infection,
autoimmune disease, sarcoidosis, and hypersensitivity
pneumonia [3]. Camus et al. [7] proposed that the differ-
ential diagnosis can be resolved by reviewing earlier imaging;
searching for extrathoracic involvement, which is typically
absent in IPPFE; and performing appropriate laboratory
tests for infections and connective tissue diseases. In our
study, we performed these examinations and could dis-
criminate other types of upper lobe fibrosis.
5. Conclusions
,e clinical features of IPPFE diagnosed using HRCT were
consistent with the characteristics of pathologically di-
agnosed patients with PPFE and differed from those of IPF.
IPPFE prognosis is worse than IPF prognosis. ,e clinical
diagnostic criteria for IPPFE still need to be established.
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